Details for Patent: 9,132,093

Which drugs does patent 9,132,093 protect, and when does it expire?

Patent 9,132,093 protects UCERIS and is included in one NDA.

This patent has twenty-six patent family members in seventeen countries.

Summary for Patent: 9,132,093

Title:	Controlled release and taste making oral pharmaceutical composition
Abstract:	Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
Inventor(s):	Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
Assignee:	Cosmo Technologies Ltd
Application Number:	US13/585,190
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,132,093
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,132,093

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix	UCERIS	budesonide	TABLET, EXTENDED RELEASE;ORAL	203634-001	Jan 14, 2013	AB	RX	Yes	Yes	9,132,093		Y

International Family Members for US Patent 9,132,093

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	251449
Australia	5680100
Canada	2377301